Nafamostat free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 330245

CAS#: 81525-10-2 (free base)

Description: Nafamostat, also known as FUT-175, is a serine protease inhibitor and an anticoagulant. Nafamostat promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway. Nafamostat Attenuates Ischemia-Reperfusion-Induced Renal Injury. Nafamostat Attenuates Ischemia-Reperfusion-Induced Renal Injury. Nafamostat protects against acute cerebral ischemia via blood-brain barrier protection. Nafamostat Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production. Researchers have identified the drug as a potential therapy for COVID-19,[ with clinical trials in Japan possibly set to begin in March 2020.


Chemical Structure

img
Nafamostat free base
CAS# 81525-10-2 (free base)

Theoretical Analysis

MedKoo Cat#: 330245
Name: Nafamostat free base
CAS#: 81525-10-2 (free base)
Chemical Formula: C19H17N5O2
Exact Mass: 347.14
Molecular Weight: 347.378
Elemental Analysis: C, 65.69; H, 4.93; N, 20.16; O, 9.21

Price and Availability

Size Price Availability Quantity
1g USD 2950 1-2 months
2g USD 5250 1-2 months
5g USD 8950 1-2 months
Bulk inquiry

Related CAS #: 81525-10-2 (free base)   82956-11-4 (mesylate)   80251-32-7 (HCl)    

Synonym: Nafamostat free base; Nafamostat; FUT-175; FUT 175; FUT175.

IUPAC/Chemical Name: 6-Amidino-2-naphthyl 4-guanidinobenzoate

InChi Key: MQQNFDZXWVTQEH-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)

SMILES Code: O=C(OC1=CC=C2C=C(C(N)=N)C=CC2=C1)C3=CC=C(NC(N)=N)C=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target: Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant.
In vitro activity: Nafamostat mesilate (NM), a serine protease inhibitor that is frequently used in the clinic, potently suppressed interferon-gamma (IFN-gamma)-induced up-regulation of PD-L1 in cultured human lung cancer cells (HLC-1) at both the messenger RNA (mRNA) and protein levels. Reference: Int Immunopharmacol. 2018 Jan;54:39-45. https://pubmed.ncbi.nlm.nih.gov/29100036/
In vivo activity: FUT-175 (6-amidino-2-naphthyl p-guanidinobenzoate dimethanesulphonate), a new synthetic protease inhibitor, was administrated to (NZB x NZB) F1 mice in order to examine its influence on the development of autoimmune diseases. A dose (400 mg/kg of body weight) of FUT-175 has both prophylactic and curative effects on the development of lupus nephritis: mice showed a significantly low percentage of proteinuria, a marked decrease in BUN levels, and the lowest degree of glomerular damages. Reference: Immunology. 1985 Aug;55(4):595-600. https://pubmed.ncbi.nlm.nih.gov/4018844/

Preparing Stock Solutions

The following data is based on the product molecular weight 347.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Morimoto M, Toyoda H, Niwa K, Hanaki R, Okuda T, Nakato D, Amano K, Iwamoto S, Hirayama M. Nafamostat mesylate prevents metastasis and dissemination of neuroblastoma through vascular endothelial growth factor inhibition. Mol Clin Oncol. 2022 Jul 21;17(3):138. doi: 10.3892/mco.2022.2571. PMID: 35949892; PMCID: PMC9353881. 2. Homma S, Hayashi K, Yoshida K, Sagawa Y, Kamata Y, Ito M. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. Int Immunopharmacol. 2018 Jan;54:39-45. doi: 10.1016/j.intimp.2017.10.016. Epub 2017 Oct 28. PMID: 29100036. 3. Matsubara H, Imai T, Tsuji S, Oka N, Egashira Y, Enomoto Y, Nakayama N, Nakamura S, Shimazawa M, Iwama T, Hara H. Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice. J Pharmacol Sci. 2022 Jan;148(1):65-72. doi: 10.1016/j.jphs.2021.10.007. Epub 2021 Oct 23. Erratum in: J Pharmacol Sci. 2022 Feb;148(2):279. PMID: 34924132. 4. Ikehara S, Shimamura K, Aoyama T, Fujii S, Hamashima Y. Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice. Immunology. 1985 Aug;55(4):595-600. PMID: 4018844; PMCID: PMC1453784.
In vitro protocol: 1. Morimoto M, Toyoda H, Niwa K, Hanaki R, Okuda T, Nakato D, Amano K, Iwamoto S, Hirayama M. Nafamostat mesylate prevents metastasis and dissemination of neuroblastoma through vascular endothelial growth factor inhibition. Mol Clin Oncol. 2022 Jul 21;17(3):138. doi: 10.3892/mco.2022.2571. PMID: 35949892; PMCID: PMC9353881. 2. Homma S, Hayashi K, Yoshida K, Sagawa Y, Kamata Y, Ito M. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. Int Immunopharmacol. 2018 Jan;54:39-45. doi: 10.1016/j.intimp.2017.10.016. Epub 2017 Oct 28. PMID: 29100036.
In vivo protocol: 1. Matsubara H, Imai T, Tsuji S, Oka N, Egashira Y, Enomoto Y, Nakayama N, Nakamura S, Shimazawa M, Iwama T, Hara H. Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice. J Pharmacol Sci. 2022 Jan;148(1):65-72. doi: 10.1016/j.jphs.2021.10.007. Epub 2021 Oct 23. Erratum in: J Pharmacol Sci. 2022 Feb;148(2):279. PMID: 34924132. 2. Ikehara S, Shimamura K, Aoyama T, Fujii S, Hamashima Y. Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice. Immunology. 1985 Aug;55(4):595-600. PMID: 4018844; PMCID: PMC1453784.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Chen X, Xu Z, Zeng S, Wang X, Liu W, Qian L, Wei J, Yang X, Shen Q, Gong Z, Yan Y. The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications. Front Oncol. 2019 Sep 3;9:852. doi: 10.3389/fonc.2019.00852. PMID: 31552177; PMCID: PMC6733886.

2: Komi DEA, Redegeld FA. Role of Mast Cells in Shaping the Tumor Microenvironment. Clin Rev Allergy Immunol. 2019 Jun 29. doi: 10.1007/s12016-019-08753-w. Epub ahead of print. PMID: 31256327.

3: Doi K, Nishida O, Shigematsu T, Sadahiro T, Itami N, Iseki K, Yuzawa Y, Okada H, Koya D, Kiyomoto H, Shibagaki Y, Matsuda K, Kato A, Hayashi T, Ogawa T, Tsukamoto T, Noiri E, Negi S, Kamei K, Kitayama H, Kashihara N, Moriyama T, Terada Y; Japanese Clinical Practice Guideline for Acute Kidney Injury 2016 Committee. The Japanese clinical practice guideline for acute kidney injury 2016. Clin Exp Nephrol. 2018 Oct;22(5):985-1045. doi: 10.1007/s10157-018-1600-4. PMID: 30039479; PMCID: PMC6154171.

4: Ghali MGZ, Srinivasan VM, Johnson J, Kan P, Britz G. Therapeutically Targeting Platelet-Derived Growth Factor-Mediated Signaling Underlying the Pathogenesis of Subarachnoid Hemorrhage-Related Vasospasm. J Stroke Cerebrovasc Dis. 2018 Sep;27(9):2289-2295. doi: 10.1016/j.jstrokecerebrovasdis.2018.02.017. Epub 2018 Jul 20. PMID: 30037648.

5: Sadahiro T, Yuzawa H, Kimura T, Oguchi M, Morito T, Mizushima S, Hirose Y. Current Practices in Acute Blood Purification Therapy in Japan and Topics for Further Study. Contrib Nephrol. 2018;196:209-214. doi: 10.1159/000485724. Epub 2018 Jul 24. PMID: 30041229.

6: Yahata M, Sakamoto Y. [Anti DIC therapy]. Nihon Rinsho. 2016 Feb;74(2):257-61. Japanese. PMID: 26915249.

7: Leporini C, Ammendola M, Marech I, Sammarco G, Sacco R, Gadaleta CD, Oakley C, Russo E, De Sarro G, Ranieri G. Targeting mast cells in gastric cancer with special reference to bone metastases. World J Gastroenterol. 2015 Oct 7;21(37):10493-501. doi: 10.3748/wjg.v21.i37.10493. PMID: 26457010; PMCID: PMC4588072.

8: Uwagawa T, Yanaga K. Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. Surg Today. 2015 Dec;45(12):1481-8. doi: 10.1007/s00595-015-1129-z. Epub 2015 Feb 12. PMID: 25673034.

9: Kubiliun NM, Adams MA, Akshintala VS, Conte ML, Cote GA, Cotton PB, Dumonceau JM, Elta GH, Fogel EL, Freeman ML, Lehman GA, Naveed M, Romagnuolo J, Scheiman JM, Sherman S, Singh VK, Elmunzer BJ; United States Cooperative for Outcomes Research in Endoscopy (USCORE). Evaluation of Pharmacologic Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Systematic Review. Clin Gastroenterol Hepatol. 2015 Jul;13(7):1231-9; quiz e70-1. doi: 10.1016/j.cgh.2014.11.038. Epub 2015 Jan 9. PMID: 25579870.

10: Hanafusa N. Application of Continuous Renal Replacement Therapy: What Should We Consider Based on Existing Evidence? Blood Purif. 2015;40(4):312-9. doi: 10.1159/000441579. Epub 2015 Nov 17. PMID: 26657106.

11: Ribatti D, Ranieri G. Tryptase, a novel angiogenic factor stored in mast cell granules. Exp Cell Res. 2015 Mar 15;332(2):157-62. doi: 10.1016/j.yexcr.2014.11.014. Epub 2014 Dec 3. PMID: 25478999.

12: Marech I, Ammendola M, Gadaleta C, Zizzo N, Oakley C, Gadaleta CD, Ranieri G. Possible biological and translational significance of mast cells density in colorectal cancer. World J Gastroenterol. 2014 Jul 21;20(27):8910-20. doi: 10.3748/wjg.v20.i27.8910. PMID: 25083063; PMCID: PMC4112891.

13: Al-Horani RA, Desai UR. Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders. Med Res Rev. 2014 Nov;34(6):1168-216. doi: 10.1002/med.21315. Epub 2014 Mar 21. PMID: 24659483.

14: Ammendola M, Leporini C, Marech I, Gadaleta CD, Scognamillo G, Sacco R, Sammarco G, De Sarro G, Russo E, Ranieri G. Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy. Biomed Res Int. 2014;2014:154702. doi: 10.1155/2014/154702. Epub 2014 Sep 11. PMID: 25295247; PMCID: PMC4177740.

15: Wada H, Matsumoto T, Yamashita Y. [Recent therapeutic strategy for disseminated intravascular coagulation]. Rinsho Ketsueki. 2014 Jan;55(1):75-82. Japanese. PMID: 24492040.

16: Tauchi R, Imagama S, Ito Z, Ando K, Hirano K, Ukai J, Kobayashi K, Shinjo R, Muramoto A, Nakashima H, Matsumoto T, Ishiguro N. Acute pancreatitis after spine surgery: a case report and review of literature. Eur J Orthop Surg Traumatol. 2014 Jul;24 Suppl 1:S305-9. doi: 10.1007/s00590-013-1390-z. Epub 2013 Dec 8. PMID: 24318308.

17: Akshintala VS, Hutfless SM, Colantuoni E, Kim KJ, Khashab MA, Li T, Elmunzer BJ, Puhan MA, Sinha A, Kamal A, Lennon AM, Okolo PI, Palakurthy MK, Kalloo AN, Singh VK. Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis. Aliment Pharmacol Ther. 2013 Dec;38(11-12):1325-37. doi: 10.1111/apt.12534. Epub 2013 Oct 20. PMID: 24138390.

18: Dhand A, Aminoff MJ. The neurology of itch. Brain. 2014 Feb;137(Pt 2):313-22. doi: 10.1093/brain/awt158. Epub 2013 Jun 22. PMID: 23794605.

19: Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013 Dec 15;56(3):232-9. doi: 10.1016/j.molimm.2013.05.221. Epub 2013 Jun 17. Erratum in: Mol Immunol. 2014 Aug;60(2):115. PMID: 23787367.

20: Yuhara H, Ogawa M, Kawaguchi Y, Igarashi M, Shimosegawa T, Mine T. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis. J Gastroenterol. 2014 Mar;49(3):388-99. doi: 10.1007/s00535-013-0834-x. Epub 2013 May 30. PMID: 23720090.